Pilot study shows preoperative dupilumab lowers polyp recurrence in CRSwNP patients, suggesting long-term benefits.
Preoperative neoadjuvant dupilumab (two doses) combined with full-house endoscopic sinus surgery (ESS) eliminates polyp recurrence at 12 months versus 50% recurrence in ESS-only cohort. Dupilumab-ESS cohort showed superior objective outcomes but comparable subjective symptom relief in this pilot study. "Neoadjuvant therapy" may reduce long-term biologic dependency and costs, while enabling sustained control with topical corticosteroids postoperatively.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: